

I hereby certify that, on the date shown below, this correspondence, including listed enclosures, is being:	
<input type="checkbox"/>	deposited with the United States Postal Service in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450,
<input type="checkbox"/>	under 37 CFR § 1.8(a), with sufficient postage as first class mail, or
<input type="checkbox"/>	under 37 CFR § 1.10, as "Express Mail Post Office to Addressee" Mailing Label No. _____
<input type="checkbox"/>	transmitted by facsimile to the Patent and Trademark Office,
	Fax Number _____
<input checked="" type="checkbox"/>	transmitted via the Office electronic filing system in accordance with 37 CFR § 1.6(a)(4)
Date: <u>29 July 2009</u>	By: <u>/Susan J. Myers Fitch/</u> Susan J. Myers Fitch

**PATENT IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF: Yuan, *et al.*

APPLICATION NO.: 10/591,358

FILED: 12 August 2008

FOR: **TRIPOLIDE LACTONE RING DERIVATIVES  
AS IMMUNOMODULATORS AND  
ANTICANCER AGENTS**

EXAMINER: CHANDRAKUMAR, Nizal S.

ART UNIT: 1625

CONFIRMATION No.: 9546

**RESPONSE TO RESTRICTION REQUIREMENT UNDER 37 C.F.R. § 1.142**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Applicants have considered the Requirement for Restriction mailed 29 June 2009 in the above-identified application. Applicants elect to prosecute the claims of Group 2, Claims 14-20, without traverse. Applicants understand upon allowance of Group 2 product claims, the withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim are entitled to rejoinder under 37 C.F.R. § 1.104.

**Amendments to the Claims** begin on page 2.

**Remarks** begin on page 5 of this paper.